Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Primary Purpose
Type2 Diabetes
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Afrezza Inhalant Product
Sponsored by

About this trial
This is an interventional treatment trial for Type2 Diabetes focused on measuring inhaled insulin
Eligibility Criteria
Inclusion Criteria:
- Adult type 2 diabetes patients age 18 or older
- HbA1c ≥ 7.5% and ≤ 11.5% after at least 6 months treatment with diabetes medication. Treatment may include oral agents, basal insulin or GLP-1 in any combination.
- Patient and provider agree not to add additional diabetes medications during the 14 weeks of the study (unless rescue treatment is indicated).
Exclusion Criteria:
- History of asthma, COPD or smoking within 6 months
- FEV1 under 70% predicted
- Pregnancy
- Active malignancies and/or life expectancy of < 12 months
- Major surgery planned during study period
- Currently using rapid acting insulins - Novolog, Humalog, Apidra
- Prior use of Afrezza in the last 3 months
- Unwilling to test blood glucose before or after each meal
- Exposure to systemic glucocorticoids within 6 weeks of screening
- Severe hypoglycemia in last 6 months or hypoglycemia unawareness
- Any medical condition which, in the opinion of the PI, would interfere with ability to understand or respond to the administration of inhaled insulin
Sites / Locations
- MODEL Clinical Research
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Afrezza Inhalant Product
Arm Description
Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
Outcomes
Primary Outcome Measures
Percentage change from baseline HbA1c
Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
Secondary Outcome Measures
Percentage of patients having HbA1c under 7%
Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS
Demonstrate that the addition of mealtime Afrezza can lower blood glucose in uncontrolled type 2 diabetes patients.
Full Information
NCT ID
NCT03324776
First Posted
October 25, 2017
Last Updated
September 14, 2020
Sponsor
Model Clinical Research LLC
Collaborators
Mannkind Corporation
1. Study Identification
Unique Protocol Identification Number
NCT03324776
Brief Title
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Official Title
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
October 16, 2017 (Actual)
Primary Completion Date
June 10, 2020 (Actual)
Study Completion Date
June 10, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Model Clinical Research LLC
Collaborators
Mannkind Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
Detailed Description
Clinical inertia in intensifying treatment of type 2 diabetes patients occurs in the range of 70% in numerous real world database assessments. The investigator proposes treating patients with Afrezza who have an index HbA1c between 7.5% and 11.5% despite being treated with diabetes medications for at least 6 months. The response to Afrezza will be assessed with Continuous Glucose Monitoring Systems (CGMS) studies and initial and follow-up HbA1cs. The goal is to assess how the investigator can rapidly and safely initiate intensification in this patient population, where extensive delays in HbA1c improvement often occur.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes
Keywords
inhaled insulin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Afrezza Inhalant Product
Arm Type
Other
Arm Description
Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
Intervention Type
Drug
Intervention Name(s)
Afrezza Inhalant Product
Other Intervention Name(s)
Afrezza Inhaled Insulin
Intervention Description
Mealtime Ultra-Rapid Acting Insulin
Primary Outcome Measure Information:
Title
Percentage change from baseline HbA1c
Description
Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Percentage of patients having HbA1c under 7%
Description
Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
Time Frame
3 months
Title
Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS
Description
Demonstrate that the addition of mealtime Afrezza can lower blood glucose in uncontrolled type 2 diabetes patients.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult type 2 diabetes patients age 18 or older
HbA1c ≥ 7.5% and ≤ 11.5% after at least 6 months treatment with diabetes medication. Treatment may include oral agents, basal insulin or GLP-1 in any combination.
Patient and provider agree not to add additional diabetes medications during the 14 weeks of the study (unless rescue treatment is indicated).
Exclusion Criteria:
History of asthma, COPD or smoking within 6 months
FEV1 under 70% predicted
Pregnancy
Active malignancies and/or life expectancy of < 12 months
Major surgery planned during study period
Currently using rapid acting insulins - Novolog, Humalog, Apidra
Prior use of Afrezza in the last 3 months
Unwilling to test blood glucose before or after each meal
Exposure to systemic glucocorticoids within 6 weeks of screening
Severe hypoglycemia in last 6 months or hypoglycemia unawareness
Any medical condition which, in the opinion of the PI, would interfere with ability to understand or respond to the administration of inhaled insulin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Levin, MD
Organizational Affiliation
Senior Director of MODEL Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
MODEL Clinical Research
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
We'll reach out to this number within 24 hrs